US House appropriators addressed the so-called regulatory "dead zone" for insulin products about to switch from regulation as drugs to regulation as biologics, although not as forcefully as recently-proposed Senate legislation.
Language in the report accompanying the House fiscal year 2020 Agriculture, Rural Development and US Food and Drug Administration appropriations bill, which was marked up and sent to the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?